Pharma companies settle bowel disease drug dispute
Pharmaceutical companies from Canada and Italy have agreed to settle a US$365 million ICC dispute over the development of a drug used in the treatment of inflammatory bowel disease.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.